Latigo Biotherapeutics (NASDAQ:LTGO) Upgraded by Jefferies Financial Group to “Strong-Buy” Rating

Jefferies Financial Group upgraded shares of Latigo Biotherapeutics (NASDAQ:LTGO) to a strong-buy rating in a research note issued to investors on Tuesday morning,Zacks reports.

Several other brokerages also recently commented on LTGO. Guggenheim started coverage on Latigo Biotherapeutics in a research note on Tuesday. They set a “buy” rating and a $50.00 price objective on the stock. The Goldman Sachs Group initiated coverage on Latigo Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $73.00 price target on the stock. Leerink Partners started coverage on Latigo Biotherapeutics in a research report on Tuesday. They issued an “outperform” rating and a $36.00 price objective for the company. Finally, Wall Street Zen raised Latigo Biotherapeutics to a “hold” rating in a research note on Saturday, August 15th. Four analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Strong Buy” and a consensus target price of $52.25.

Latigo Biotherapeutics Stock Up 1.1%

Shares of NASDAQ LTGO opened at $22.26 on Tuesday. Latigo Biotherapeutics has a 52-week low of $17.22 and a 52-week high of $25.93.

Insider Activity at Latigo Biotherapeutics

In other news, major shareholder Foresite Capital Management V, purchased 140,000 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were purchased at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the purchase, the insider owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This trade represents a 7.49% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director James B. Tananbaum bought 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the acquisition, the director directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. The trade was a 7.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Key Latigo Biotherapeutics News

Here are the key news stories impacting Latigo Biotherapeutics this week:

• Positive Sentiment: Multiple analyst upgrades: Leerink Partners, Jefferies Financial Group, Guggenheim, and Goldman Sachs each upgraded Latigo to “strong-buy.” The broad agreement among analysts may improve investor confidence and increase demand for LTGO shares.
• Positive Sentiment: Goldman Sachs initiates Buy rating: Analyst Salveen Richter cited Latigo’s differentiated non-opioid pain platform and Nav1.8 pipeline, along with the potential for significant peak sales. The thesis suggests investors see commercial opportunity in Latigo’s approach to pain treatment without opioids. Salveen Richter Initiates Buy on Latigo for Differentiated Non-Opioid Pain Platform and Nav1.8 Pipeline with Strong Peak Sales Potential
• Neutral Sentiment: Investor focus remains on the pipeline: Latigo’s valuation and future stock performance will likely depend on clinical progress, regulatory milestones, and whether its Nav1.8 candidates can demonstrate meaningful efficacy and safety in pain indications.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.